Abstract

This is a historical moment on the path to genomic medicine — the point at which theory is about to be translated into practice. We have previously described human genome variation studies taking place in Mexico, India, Thailand, and South Africa. Such investments into science and technology will enable these countries to embark on the path to the medical and health applications of genomics, and to benefit economically. Here we provide a perspective on the challenges and opportunities facing these and other countries in the developing world as they begin to harness genomics for the benefit of their populations.

Author affiliations

1. Billie-Jo Hardy, Béatrice Séguin, Peter A. Singer and Abdallah S. Daar are at the McLaughlin–Rotman Centre for Global Health, Program on Life Sciences, Ethics and Policy, University Health Network and University of Toronto, MaRS Centre, South Tower, Suite 406, 101 College Street, Toronto, Ontario M5G 1L7, Canada.
2. Federico Goodsaid is at the Genomics Group, Office of Clinical Pharmacology, Office of Translational Science, Center for Drug Evaluation and Research, US Food and Drug Administration, 10903 New Hampshire Avenue, Building 51, Room 2148, Silver Spring, Maryland 20903-0002, USA.
3. Gerardo Jimenez-Sanchez is at the National Institute of Genomic Medicine, Periferico Sur 4124, Torre Zafiro II, Piso 6 Col. Jardines del Pedregal, Mexico D.F. 01900, Mexico.
4. Béatrice Séguin is also at the Leslie Dan Faculty of Pharmacy, University of Toronto, 144 College Street, Toronto, Ontario M5S 3M2, Canada.
5. Peter A. Singer and Abdallah S. Daar are also at the McLaughlin Centre for Molecular Medicine, MaRS Centre, Toronto Medical Discovery Tower, Suite 701, 101 College Street, Toronto, Ontario M5G 1L7, Canada.

Correspondence to: Abdallah S. Daar^1,5 Email: a.daar@utoronto.ca

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.